About Argenta

Collaborations

Argenta is pursuing fee-for-service agreements with a broad range of pharmaceutical and biotechnology companies.

Examples of recent fee-for-service agreements:

• Almac Discovery (Craigavon, UK)
  Scientists from Argenta and Almac are working together to advance one of Almac's portfolio of high-value cancer programmes from hit identification to development candidate. Argenta will provide medicinal and computational chemistry services and know-how, and Almac will contribute medicinal chemistry, biochemistry and in vitro screening capabilities and expertise.
  
  
• Antisoma (London, UK)
  Argenta and Antisoma collaborated to develop improved anti-cancer telomere targeting agents.  During the project, Antisoma utilised Argenta’s expertise in medicinal and computational chemistry, molecular biology, biochemistry and in vitro screening.
  
  
• AstraZeneca (USA, Sweden and UK)
  As part of a four-year collaboration, Argenta provided discovery research capabilities to AstraZeneca. The most recent project involved Argenta scientists providing medicinal chemistry resource and know how to support drug discovery activities for AZ in Wilmington, DE.
  
  
• BioTie Therapies Corp. (Turku, Finland)
  During a lead optimisation collaboration, scientists from the two companies exploited Argenta's expertise in medicinal and computational chemistry to advance one of BioTie's novel therapeutics programmes towards development candidate nomination.
  
  
• CellCentric (Cambridge, UK)
  Under the terms of the agreement, scientists from the two companies are exploiting Argenta's expertise in virtual screening, molecular biology, biochemical assay development and in vitro screening to discover inhibitors for a number of potential epigenetic-related therapeutic targets.
  
  
• Genentech (South San Francisco, USA)
  In the course of six major drug discovery collaborations, scientists from Argenta and Genentech are applying their expertise in medicinal and computational chemistry, biochemistry and DMPK to discover NCEs acting against undisclosed drug targets..
  
  
• Novartis
  In a two-year drug discovery collaboration, an integrated team of Argenta and Novartis scientists worked on a programme that centred on the search for new diabetes therapies.
  
  
• Zafgen (Cambridge, USA)
  Scientists from the two companies are exploiting Argenta's expertise in medicinal and computational chemistry, biochemistry, in vitro screening, and DMPK to accelerate development candidate nomination for one of Zafgen's innovative therapeutics programmes for obesity.

Please click here for a summary of typical multidisciplinary projects that Argenta undertakes in hit identification, hit-to-lead and lead optimisation.